Technical Analysis for AIM - AIM ImmunoTech Inc.

Grade Last Price % Change Price Change
F 0.40 3.33% 0.01
AIM closed up 3.33 percent on Friday, May 17, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Gapped Up Strength 0.00%
20 DMA Resistance Bearish 3.33%
Gapped Up Strength 3.33%
NR7 Range Contraction 0.85%
Inside Day Range Contraction 0.85%

   Recent Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

AIM ImmunoTech Inc. Description

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Disease Acid Infectious Diseases Health Care Melanoma Pancreatic Cancer Hepatitis B Carcinoma HIV Interferon Renal Cell Carcinoma Treatment Of Hepatitis Treatment Of Hepatitis B Chronic Fatigue Syndrome

Is AIM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.7487
52 Week Low 0.3201
Average Volume 263,184
200-Day Moving Average 0.48
50-Day Moving Average 0.43
20-Day Moving Average 0.41
10-Day Moving Average 0.41
Average True Range 0.04
RSI (14) 45.65
ADX 23.21
+DI 13.16
-DI 19.66
Chandelier Exit (Long, 3 ATRs) 0.37
Chandelier Exit (Short, 3 ATRs) 0.49
Upper Bollinger Bands 0.44
Lower Bollinger Band 0.38
Percent B (%b) 0.35
BandWidth 14.13
MACD Line -0.01
MACD Signal Line -0.01
MACD Histogram -0.0017
Fundamentals Value
Market Cap 19.68 Million
Num Shares 48.8 Million
EPS -0.43
Price-to-Earnings (P/E) Ratio -0.94
Price-to-Sales 100.75
Price-to-Book 0.89
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.45
Resistance 3 (R3) 0.45 0.44 0.44
Resistance 2 (R2) 0.44 0.43 0.44 0.44
Resistance 1 (R1) 0.42 0.42 0.41 0.42 0.43
Pivot Point 0.41 0.41 0.41 0.41 0.41
Support 1 (S1) 0.39 0.40 0.39 0.39 0.37
Support 2 (S2) 0.38 0.39 0.38 0.37
Support 3 (S3) 0.36 0.38 0.37
Support 4 (S4) 0.36